4//SEC Filing
Bain Capital Life Sciences Investors, LLC 4
Accession 0000950170-25-004870
CIK 0001750284other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:34 PM ET
Size
28.4 KB
Accession
0000950170-25-004870
Insider Transaction Report
Form 4
Transactions
- Other
Common Stock
2025-01-10−3,500,000→ 4,300,000 total(indirect: See footnotes) - Other
Pre-Funded Warrant (right to buy)
2025-01-10+3,500,000→ 3,500,000 total(indirect: See footnotes)Exercise: $0.00From: 2025-01-13→ Common Stock (3,500,000 underlying) - Purchase
Common Stock
2025-01-08$5.76/sh+300,000$1,727,370→ 7,800,000 total(indirect: See footnotes)
Transactions
- Other
Common Stock
2025-01-10−3,500,000→ 4,300,000 total(indirect: See footnotes) - Purchase
Common Stock
2025-01-08$5.76/sh+300,000$1,727,370→ 7,800,000 total(indirect: See footnotes) - Other
Pre-Funded Warrant (right to buy)
2025-01-10+3,500,000→ 3,500,000 total(indirect: See footnotes)Exercise: $0.00From: 2025-01-13→ Common Stock (3,500,000 underlying)
Transactions
- Purchase
Common Stock
2025-01-08$5.76/sh+300,000$1,727,370→ 7,800,000 total(indirect: See footnotes) - Other
Common Stock
2025-01-10−3,500,000→ 4,300,000 total(indirect: See footnotes) - Other
Pre-Funded Warrant (right to buy)
2025-01-10+3,500,000→ 3,500,000 total(indirect: See footnotes)Exercise: $0.00From: 2025-01-13→ Common Stock (3,500,000 underlying)
Transactions
- Other
Common Stock
2025-01-10−3,500,000→ 4,300,000 total(indirect: See footnotes) - Purchase
Common Stock
2025-01-08$5.76/sh+300,000$1,727,370→ 7,800,000 total(indirect: See footnotes) - Other
Pre-Funded Warrant (right to buy)
2025-01-10+3,500,000→ 3,500,000 total(indirect: See footnotes)Exercise: $0.00From: 2025-01-13→ Common Stock (3,500,000 underlying)
Transactions
- Purchase
Common Stock
2025-01-08$5.76/sh+300,000$1,727,370→ 7,800,000 total(indirect: See footnotes) - Other
Pre-Funded Warrant (right to buy)
2025-01-10+3,500,000→ 3,500,000 total(indirect: See footnotes)Exercise: $0.00From: 2025-01-13→ Common Stock (3,500,000 underlying) - Other
Common Stock
2025-01-10−3,500,000→ 4,300,000 total(indirect: See footnotes)
Footnotes (6)
- [F1]Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").
- [F2]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F4]On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities.
- [F5]BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.
- [F6]The pre-funded warrant does not expire.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001703031
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 4:34 PM ET
- Size
- 28.4 KB